SOURCE beyond first‐line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first‐line palliative systemic therapy. Issue 6 (9th December 2022)

• Record Type: Journal Article
• Authors: Kuijper, Steven C.; Pape, Marieke; Haj Mohammad, Nadia; van Voorthuizen, Theo; Verhoeven, Rob H. A.; van Laarhoven, Hanneke W. M.
• Is Part Of: International journal of cancer. Volume 152:Issue 6(2023)
• Page Start: 1202
• Page End: 1209
• Publication Date: 2022-12-09
• Subjects: best supportive care -- esophageal cancer -- gastric cancer -- prediction model -- second‐line; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.34385
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract: Prior models have been developed to predict survival for patients with esophagogastric cancer undergoing curative treatment or first‐line chemotherapy (SOURCE models). Comprehensive clinical prediction models for patients with esophagogastric cancer who will receive second‐line chemotherapy or best supportive care are currently lacking. The aim of our study was to develop and internally validate a new clinical prediction model, called SOURCE beyond first‐line, for survival of patients with metastatic esophagogastric adenocarcinoma after failure of first‐line palliative systemic therapy. Patients with unresectable or metastatic esophageal or gastric adenocarcinoma (2015‐2017) who received first‐line systemic therapy (N = 1067) were selected from the Netherlands Cancer Registry. Patient, tumor and treatment characteristics at primary diagnosis and at progression of disease were used to develop the model. A Cox proportional hazards regression model was developed through forward and backward selection using Akaike's Information Criterion. The model was internally validated through 10‐fold cross‐validations to assess performance. Model discrimination (C‐index) and calibration (slope and intercept) were used to evaluate performance of the complete and cross‐validated models. The final model consisted of 11 patient tumor and treatment characteristics. The C‐index was 0.75 (0.73‐0.78), calibration slope 1.01 (1.00‐1.01) and calibration intercept 0.01 (0.01‐0.02). Internal cross‐validation of the model showed that the model performed adequately on unseen data: C‐index was 0.79 (0.77‐0.82), calibration slope 0.93 (0.85‐1.01) and calibration intercept 0.02 (−0.01 to 0.06). The SOURCE beyond first‐line model predicted survival with fair discriminatory ability and good calibration. Abstract : What's new? Patients with metastatic esophagogastric cancer generally have poor survival. Here, the authors present a model for predicting survival after failure of first‐line palliative systemic treatment. They collected data from 1067 patients in the Netherlands Cancer Registry who had unresectable or metastatic esophageal or gastric adenocarcinoma. Unlike existing models, this model includes information about second‐line chemotherapies and best supportive care, and was developed on a large number of patients. The final model included 11 different characteristics of the patient, tumor, and treatment, and could help patients and providers make informed decisions about starting second‐line therapies.